



JC06 Rec'd PCPTO 09 SEP 2005 PCT

Date: September 8, 2005 I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum
Name (Print)

Kim Blum
Signature

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	DOI et al.)	Examiner:	Unassigned
)		
Application No.:	10/519,465)	Group Art Unit:	Unassigned
)		
Filed:	December 27, 2004)	Confirmation No.:	7622
)		
Docket No.:	3190-069)	Customer No.:	33432

For: MKK7 ACTIVATION INHIBITOR

**RESPONSE TO NOTIFICATION TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 8, 2005

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated August 9, 2005, the applicants respond as follows.

In the Notification, it was asserted that the content of the computer readable form does not comply with the requirements of 37 C.F.R. §1.822 and/or § 1.823.

To fully respond to this Notification, enclosed is a second diskette containing a computer readable form of the "Sequence Listing." This is a substitute computer readable form (CRF) copy of the "Sequence Listing." Also enclosed is a Statement under 37 C.F.R. § 1.821, along with a printed version of the "Sequence Listing." The printed version of the "Sequence Listing" has been

Response to Notification to Comply With Requirements
for Patent Applications Containing Nucleotide
and/or Amino Acid Sequence Disclosures
U.S. Patent Application No. 10/519,465


updated to reflect the current assigned U.S. patent application number for the present application and to remove the page numbering. Accordingly, the applicants have fully responded to the notification.

CONCLUSION

In view of the foregoing remarks, the applicant respectfully requests the reconsideration of this application and the timely allowance of the pending claims.

If there are any fees due in connection with the filing of this response, please charge the fees to Deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such extension is requested and should also be charged to said Deposit Account.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No. 3190-069
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720

Enclosures: Statement Under 37 C.F.R. § 1.821
Printed version of the "Sequence Listing"
Diskette containing a computer readable form of the "Sequence Listing."
Copy of Notice to Comply with Requirements



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/519,465	Hirofumi Doi	3190-069

INTERNATIONAL APPLICATION NO.

PCT/JP03/08179

I.A. FILING DATE

06/27/2003

PRIORITY DATE

06/28/2002

Kilyk & Bowersox
 53 A East Lee street
 Warrenton, VA 20186

CONFIRMATION NO. 7622

371 FORMALITIES LETTER



OC000000016705199

Date Mailed: 08/09/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application** OR a substitute computer readable form (CRF) copy of the "Sequence Listing". two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/519,465	PCT/JP03/08179	3190-069

FORM PCT/DO/EO/922 (371 Formalities Notice)